Beware of new warnings for contrast agents


FDA issues new warnings about Definity and Optison contrast agents

If you're administering the micro-bubble contrast agents Definity (Perflutren Lipid Microsphere, Bristol-Myers Squibb Medical Imaging) or Optison (Perflutren Protein-Type A Microspheres for Injection, GE Healthcare), beware that the FDA has just issued new labeling that warns that these products have not been tested for safety and efficacy when used with exercise or pharmacological stress. The agency also cautioned that the products are contraindicated among patients with unstable cardiopulmonary status. For more information, refer to

Related Videos
fake news misinformation | Image Credit: Bits and Splits -
Dr. Charles Lee
Related Content
© 2024 MJH Life Sciences

All rights reserved.